AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns.

The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower base.

If you are weighing AtriCure against other opportunities in medical technology, it could be a good moment to see what stands out in the 40 healthcare AI stocks

With AtriCure trading around $28.80, recent gains sit against multi year share price pressure and ongoing net losses, leaving investors to consider whether the current level reflects an undervalued medtech specialist or whether the market is already pricing in future growth.

Most Popular Narrative: 45.4% Undervalued

AtriCure's most followed narrative points to a fair value of about $52.78 per share versus the last close of $28.80. This frames a wide valuation gap built on specific growth, margin, and earnings assumptions.

Rapid revenue growth is supported by accelerated adoption of AtriCure's innovative, minimally invasive devices like the AtriClip FLEX Mini and cryoSPHERE MAX which directly benefit from the global trend toward minimally invasive cardiac procedures and hospital prioritization of advanced surgical solutions. This increases both volumes and average selling prices, driving top line expansion.

Want to see what is behind that optimism on revenue, profitability and future earnings power? The narrative leans on ambitious growth, rising margins, and a premium future earnings multiple to support that fair value. Curious which specific forecasts and timeframes have to line up for AtriCure to reach that number.

Result: Fair Value of $52.78 (UNDERVALUED)

However, AtriCure's story could be knocked off course if pulsed field ablation competitors squeeze its ablation franchise, or if heavy R&D spending fails to translate into stronger profitability.

Another View: What AtriCure's Cash Flows Suggest

The popular narrative has AtriCure looking undervalued around $28.80 based on future earnings and multiples, but the SWS DCF model paints a very different picture. On that basis, the stock is trading well above an estimated future cash flow value of about $1.69, which points to an overvalued outcome. For you as an investor, the tension between a 45.4% discount to fair value in the narrative and a DCF that sits far below the current share price raises a simple question: which story do you trust more, the earnings path or the cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Torn between optimism and concern in AtriCure's story today? Move quickly from headline impressions to your own judgement by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond AtriCure?

If AtriCure has caught your attention, do not stop there. Use the Simply Wall Street Screener to surface other stocks that fit the way you like to invest.

• Target resilient balance sheets and steady fundamentals with the solid balance sheet and fundamentals stocks screener (48 results).
• Spot potential mispricings by scanning the 45 high quality undervalued stocks before the market catches up.
• Uncover lesser known opportunities with strong underlying metrics through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.